Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Given the market potential, strategic focus, and compelling clinical data, LLY stock represents a strong investment opportunity in the evolving obesity treatment landscape
Cagrilintide has Phase 2 and CagriSema Phase 3 data
While rare, pancreatitis risk increases in patients with personal or family history of pancreatic disease
The segment continues to gain traction due to on-the-go consumption trends
After your first month, the optional Precision Peptide Genetic Test ($298) can be added to your next order
212,213 The ongoing SURPASS-CVOT trial (NCT04255433) and SURPASS-CVOT trial (NCT06779929) aim to evaluate the impact of tirzepatide on cardiovascular outcomes compared with dulaglutide in patients with type 2 diabetes
US$ 27.59
US$ 23.18
US$ 20.95
US$ 26.41
US$ 27.55
US$ 25.69
